Scandion Oncology Q3 2023: Intriguing CORIST part 2 data - Redeye
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Aktieanalys

Scandion Oncology Q3 2023: Intriguing CORIST part 2 data - Redeye

{newsItem.title}

Redeye comments on Scandion Oncology’s Q3 2023 report, one day after the company announced intriguing final data from CORIST part 2. Final CORIST part 2 data indicated elongated survival versus cited historical controls. We believe reported data is promising. However, they require confirmation in a controlled randomised trial. We do some housekeeping in our model and finetune our estimates and valuation.

Länk till analysen i sin helhet: https://www.redeye.se/research/962275/scandion-oncology-q3-2023-intriguing-corist-part-2-data?utm_source=finwire&utm_medium=RSS

Nyheter om Scandion Oncology

Läses av andra just nu

Om aktien Scandion Oncology

Senaste nytt